Tiziana Life Sciences Ltd

Rentabilité sur six mois: +127.94%
Rendement en dividendes: 0%
Secteur: Healthcare

1.55 $

0 $ 0%
0.643 $
1.69 $

paper.min_max_per_year

Calendrier des promotions Tiziana Life Sciences Ltd

À propos de l'entreprise Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Paramètres de base

IPO date
2000-03-24
ISIN
BMG889121031
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 19.72 1
P/E 0 0
Efficacité
Nom Signification Grade
ROA -101.1 0
ROE -250.49 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0161 10
Debt/Ratio 0.0219 10
Debt/Equity 1.87 7
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -97.64 0
Rentabilité Ebitda, % 29.82 4
Rentabilité EPS, % -52.4 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.55 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.46 $ 0 $ 0 $ 6.16 % 0 % 0 %
common.calendar.number_days.30d 1.58 $ 1.37 $ 1.55 $ -1.9 % 0 % 0 %
common.calendar.number_days.90d 0.7901 $ 0.78 $ 1.62 $ 96.18 % 0 % 0 %
common.calendar.number_days.180d 0.68 $ 0.643 $ 1.69 $ 127.94 % 0 % 0 %
common.calendar.number_days.1y 1.19 $ 0.643 $ 1.69 $ 30.25 % 0 % 0 %
common.calendar.number_days.3y 0.74 $ 0.417 $ 1.69 $ 109.46 % 0 % 0 %
common.calendar.number_days.5y 5.57 $ 0.417 $ 12.26 $ -72.17 % 0 % 0 %
common.calendar.number_days.10y 0.417 $ 0.417 $ 12.26 $ 371.7 % 0 % 0 %
common.calendar.number_days.ytd 0.6783 $ 0.643 $ 1.69 $ 128.51 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO 817k 1972 (53 année)
Ms. Keeren Shah Chief Financial Officer 1976 (49 années)
Dr. William A. Clementi Ph.D., Pharm.D. Chief Development Officer
Dr. Napoleone Ferrara M.D. Member of Scientific Advisory Board 1957 (68 années)

Informations sur l'entreprise

Adresse: United Kingdom, London WS XJ, 14/15 Conduit Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.tizianalifesciences.com